What successful incretin drugs, BPC-157, and Epitalon teach us about peptide engineering, translational evidence, and the limits of molecular plausibility.
Oct 11, 2026
What EFMC-ISMC 2026 revealed about the changing practice of drug discovery: from generative chemistry and automated DMTA cycles to allosteric pockets, DMPK liabilities, and human decision-making.
Sep 21, 2026
Key takeaways from the Optibrium panel discussion featuring Nathan Brown, Charlotte Deane, Pat Walters, Chris Swain, and Paul Czodrowski on AI strategy, data leakage, generative risks, and LLMs in drug discovery.
Jul 30, 2026